The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"
Phase 3
Terminated
- Conditions
- Crohn's Disease
- Registration Number
- NCT00245505
- Lead Sponsor
- Ferring Pharmaceuticals
- Brief Summary
The purpose of this study is to visualize the healing effect on mucosal lesions with Pentasa Sachet 4g in patients with mild to moderate active small bowel CD by video capsule endoscopy.
- Detailed Description
The purpose of this study is to visualize the healing effect on mucosal lesions with Pentasa Sachet 4g in patients with mild to moderate active small bowel CD by video capsule endoscopy
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Mucosal changes, (measured as number, type and localization of small bowel mucosal lesions detected by VCE) from baseline (i.e. < 7 days prior to inclusion), and after 6 and 12 weeks´ treatment with 4g Pentasa Sachet 12 weeks
- Secondary Outcome Measures
Name Time Method CDAI changes and laboratory changes 12 weeks
Trial Locations
- Locations (1)
Department of Medicine, Malmö University Hospital
🇸🇪Malmo, Malmö, Sweden